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Abstract
Background: Concominant with the widespread use of combined immunotherapy in the management of Crohn’s disease
(CD), the incidence of hepato-splenic gamma-delta (cd)-T cell lymphoma has increased sharply in CD patients. Malignant
transformation of lymphocytes is believed to be a multistep process resulting in the selection of malignant cd-T cell clones.
We hypothesised that repeated infusion of anti-TNF-a agents may induce clonal selection and that concurrent treatment
with immunomodulators further predisposes patients to cd-T cell expansion.
Methodology/Principal Findings: We investigated dynamic changes in the cd-T cells of patient with CD following
treatment with infliximab (RemicadeH; n=20) or adalimumab (HumiraH; n=26) using flow cytometry. In patients with a high
cd-T cell level, the cd-T cells were assessed for clonality. Of these 46 CD patients, 35 had a cd-T cells level (mean 1.6%)
comparable to healthy individuals (mean 2.2%), and 11 CD patients (24%) exhibited an increased level of cd-T cells (5–15%).
In the 18 patients also receiving thiopurines or methotrexate, the average baseline cd-T cell level was 4.4%. In three male CD
patients with a high baseline value, the cd-T cell population increased dramatically following infliximab therapy. A fourth
male patient also on infliximab monotherapy presented with 20% cd-T cells, which increased to 25% shortly after treatment
and was 36% between infusions. Clonality studies revealed an oligoclonal cd-T cell pattern with dominant cd-T cell clones.
In support of our clinical findings, in vitro experiments showed a dose-dependent proliferative effect of anti-TNF-a agents
on cd-T cells.
Conclusion/Significance: CD patients treated with immunomodulators had constitutively high levels of cd-T cells. Infliximab
exacerbated clonal cd-T cell expansion in vivo and induced cd-T cell proliferation in vitro. Overall, young, male CD patients
with high baseline cd-T cell levels may be at an increased risk of developing malignant cd-T cell lymphomas following
treatment with anti-TNF-a agents.
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Introduction
T cells that express the cd subunits of the T cell receptor link
innate and adaptive immunity and have been implicated in the
pathogenesis of autoimmune diseases, particularly Crohn’s disease
(CD) [1]. The frequency of cd-T cells in the peripheral blood of
healthy individuals ranges from 2–5%. However, higher cd-T cell
frequencies have been found in CD patients [2], and these
increased levels have been reported to mirror disease activity, with
higher levels in patients with active disease[3]. Hepatosplenic T
cell lymphoma (HSTCL) is a rare and distinct peripheral T cell
lymphoma that is nearly always cd-T cell in origin[4]. HSTCL has
been observed in patients receiving immunosuppressive treatment
and in a disproportionately high number of young male CD
patients [5–7].
To date, approximately 200 cases of HSTCL have been reported
worldwide. Interestingly, of these cases, 28 cases were reported in
patients with inflammatory bowel disease (IBD). With the exception
of one case, the occurrence of anti-TNF-a treatment–associated
HSTCL has only been reported in IBD patients [5,8]. Of these 28
cases, 22 patients had received infliximab in combination with a
thiopurine analogue (azathioprine or 6-mercaptopurine) [9], 3 cases
were associated with the use of infliximab followed by adalimumab.
However, HSTCL was also reported to occur in patients receiving
azathioprine monotherapy [10,11].
In a large study conducted by CESAME, where only 9% of the
patients received anti-TNF-a therapy, evidence for a possible
causal role of thiopurines in lymphomagenesis was reported;
however, no cases of HTSCL were reported [12]. HSTCL
incidence is very low, and clinical trials may not provide a follow-
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lymphoma development in the studied cohorts. Thus, a causal
link between thiopurine treatment and the possible increased risk
of combining thiopurine treatment with anti-TNF-a agents has
been difficult to establish[13]. Furthermore, it is unknown if there
are differences in the risk associated with the various anti-TNF-a
agents. As a result of the observed HSTCL cases, a stepdown to
monotherapy has been advocated in young IBD patients [14].
However, the lymphoma risk apparently persists, as even a single
exposure to infliximab appears to predispose patients to lympho-
ma development years later [15].
The malignant transformation of lymphocyte subsets in IBD
patients is believed to be a multistep process resulting in the
selection of cd-T cell clones with a survival advantage [16]. In this
context, we hypothesised that repeated treatment with anti-TNF-a
antibodies in a standard maintenance regimen may contribute to
this process and that concomitant thiopurine treatment may
further promote cd-T cell expansion. Therefore, we examined
circulating cd-T cells in patients with active CD before and after
treatment with the anti-TNF-a antibodies infliximab (RemicadeH)
and adalimumab (HumiraH). We confirmed the hypothesis raised
by previous epidemiological studies that infliximab has a profound
proliferative effect on cd-T cells both in vivo and in vitro and that
infliximab treatment results in the clonal expansion of cd-T cells in
specific CD patients. We hypothesise that markedly elevated cd-T
cell levels may identify CD patients prone to develop lymphopro-
liferative disease during anti-TNF-a therapy.
Materials and Methods
Patients and Healthy Volunteers
We examined 46 patients with active CD, diagnosed based on
internationally accepted clinical, histopathological, and biochem-
ical criteria [17]. The patient characteristics are listed in Tables S1
and 1, and clinical disease activity was estimated using the Harvey-
Bradshaw Index (HBI) [18]. Systemic inflammation was evaluated
using C-reactive protein levels; faecal calprotectin [19] was used to
estimate mucosal inflammation. Treatment decisions were based
on the combined evaluation of clinical, biochemical, and faecal
disease markers. In total, twenty patients were treated with
infliximab (RemicadeH, Centocor; 5 mg/kg intravenously at days
0, 14, and 42), and 26 patients were treated with adalimumab
(HumiraH, Abbott). The adalimumab-treated patients received a
subcutaneous injection of 160 mg at week 0 and an injection of
80 mg at week 2. This was then followed by 40 mg maintenance
injections every 2 weeks. Blood samples were obtained immedi-
ately before the administration of the anti-TNF-a agent and at
days 1, 7, and 42 after the first treatment. One patient, number 47,
was included post-hoc for further analyses and verification of our
results. Sixteen healthy volunteers were recruited from the hospital
staff to serve as controls. All participants provided written
informed consent, and the study was approved by The Central
Denmark Region Committee on Biomedical Research Ethics
(j.no. 20040150).
Whole-blood Flow Cytometry
For flow cytometric staining, 100 ml of venous blood was
incubated for 20 minutes at room temperature with the optimised
amounts of the following fluorescent-conjugated antibodies: anti-
ab-TCR-FITC (clone WT-31), anti-Vd2-PE (clone B6), anti-CD3-
PerCP (clone SK7), anti-CD8-PE-Cy7 (clone RPA-T8), anti-cd-
TCR-APC (clone B1), and anti-CD4-APC-Cy7 (clone RPA-T4).
All antibodies were from BD Biosciences (San Diego, CA). After
10 minutes, the red blood cells were lysed using 2 ml Pharm Lyse
Buffer (BD Biosciences), and the samples were centrifuged for 5
minutes at 2006g at 20uC. The washed cells were resuspended in
200 ml phosphate-buffered saline (PBS) with 2% pooled human
AB serum and 1% formaldehyde. Six-colour flow cytometry was
performed within 4 hours on a FACSCanto flow cytometer (BD
Biosciences). For each sample, 30,000 events in the forward/side
scatter live lymphocyte gate were recorded. All cd-T cell
frequencies are out of total CD3+ T cells. The data were analysed
using FACSDiva 5.1 Software (BD Biosciences).
Proliferation Assay
Peripheral blood mononuclear cells (PBMCs) were labelled with
carboxyfluorescein succinimidyl ester (CFSE). The cells (1.5610
6
cells/ml) were cultured in RPMI 1640 supplemented with 10%
human AB serum, penicillin/streptomycin, and rIL-2 (200
IU/ml). Cells were cultured in the absence or presence of
infliximab (0.1 or 1.0 mg/ml), adalimumab (0.1 or 1.0 mg/ml) or
etanercept (1.0 mg/ml). Ustekinumab (1.0 mg/ml), an antibody
against IL-12/23(p40), was used as a control. Recombinant
human TNF-a (10 ng/ml) (Genzyme, Cambridge, MA) was
added to selected wells. Proliferation was measured on day 5
using flow cytometry, as previously described [20].
Separation of cd-T cells
PBMCs were isolated using Ficoll-Hypaque (GE Healthcare
Bio-Sciences, Uppsala, Sweden) centrifugation, and cd-T cells
were purified using the TCRc/d T Cell Isolation Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany). Cell separation was
performed on an AutoMACS Cell Separator, as recommended
by the manufacturer. For all steps of the cell separation, we used
PBS supplemented with 2 mM EDTA and 0.5% bovine serum
albumin (BSA) (Sigma-Aldrich, Denmark). The purity of the cd-T
cells ranged between 90–95%.
Preparation of Genomic DNA and Total RNA
For fragment analysis, genomic DNA was extracted from 2 ml
of EDTA-treated whole blood according to the manufacturer’s
instructions (NucleoSpin Blood L, Macherey-Nagel, Germany).
DNA was dissolved in 5 mM Tris/HCl, pH 8.5. The quality of
DNA was assessed by PCR amplification of three fragments
(195 bp, 450 bp, and 650 bp) of the p53 gene. Combined
extraction of mRNA and genomic DNA from enriched cd-T cell
Table 1. Summarised baseline characteristics.
Variable All Infliximab Adalimumab
n 46 20 26
Females, n (%) 22 (48%) 10 (50%) 12 (46%)
Age, median (range) 38 (19–67) 39 (19–61) 36 (20–67)
Smokers, n (%) 15 (33%) 5 (25%) 10 (39%)
Ileal disease, n (%) 28 (61%) 11 (55%) 17 (65%)
Colonic disease, n (%) 40 (87%) 17 (85%) 23 (89%)
Steroid, n (%) 5 (11%) 4 (20%) 1 (4%)
AZA/6MP, n (%) 15 (33%) 3 (15%) 12 (46%)
M, n (%) 3 (7%) 2 (10%) 1 (4%)
Previous infliximab, n (%) 19 (41%) 8 (40%) 11 (42%)
Previous adalimumab, n (%) 9 (20%) 1 (5%) 8 (31%)
doi:10.1371/journal.pone.0017890.t001
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tions (AllPrep DNA/RNA Mini Kit, Qiagen, Germany). The
quality of the genomic DNA was verified using PCR, as described
above, while mRNA quality was assessed using gel electrophoresis.
Multiplex PCR Assay
Identification of clonal populations with a specific T cell
receptor delta (TCRD) rearrangement was performed according
using the BIOMED-2 protocol [21], with slight modifications.
PCR analysis of TCRD rearrangements was performed in a single
tube with the TCRD primerset consisting of six Vd and one Dd2
(forward) primers or four Jd and one Dd3 primers (reverse) (Sigma
Aldrich, St. Louis, MO, USA). Fluorescent labelling of the
different Jd and Dd primers was done using HEX and 6FAM,
respectively. The identification of clonal populations was per-
formed by fragment analysis using a 3130xl genetic analyser and
the Peak Scanner 1.0 Software (Applied Biosystems, Foster City,
CA, USA). A clonal population was defined by the presence of a
single peak or a predominant population. The fragment size was
interpreted in accordance with the BIOMED-2 protocol. For all
analyses, a second, confirmatory determination was performed.
DNA Heteroduplex Analysis
To verify the fragment analysis results, PCR products were
denatured at 95uC for 5 minutes and then re-annealed at 4uC for
1 hour. Heteroduplex products were separated using 6% non-
denaturating polyacrylamide electrophoresis in 0.56TBE-buffer,
stained with 0.5 mg/ml ethidium bromide, and visualised using a
UV-transilluminator.
Statistical analysis
Both parametric and non-parametric statistical tests were used.
Unpaired bivariate comparisons of continuous variables were
carried out using the Student’s t-test. Dichotomous variables were
compared using the x
2 test. The mean and 95% confidence
intervals (CI) are reported for continuous data. All correlations
were evaluated using Spearman rho. A p value less than 0.05 was
considered statistically significant. All statistical analyses were
performed using SPSS 11.0 software.
Results
cd-T cell Characteristics of CD Patients
We recruited 46 CD patients with an even distribution of
gender and age (Tables S1 and 1). At the time of analysis, 20
patients were being treated with infliximab and 26 with
adalimumab. In the latter group, 11 patients (42%) had previously
received infliximab. Of the 46 CD patients, 35 (76%) had a cd-T
cell level comparable to the level found in healthy volunteers. CD
patients had a mean frequency of 1.6% cd-T cells of total CD3+ T
cells, with values ranging from 1.3–2.0%. Similarly, healthy
volunteers had a mean cd-T cell frequency of 2.2% with values
ranging from 1.7–2.8%. While no healthy volunteer had a cd-T
cell level above 5%, 11 CD patients (24%) exhibited a high
baseline percentage of cd-T cells, with frequencies ranging from
5% to 15% Of these 11 patients, all were non-smokers (p=0.008,
x
2 test), and all had colonic inflammation (p=0.14, x
2 test). Of the
11 patients, 8 were males (p=0.12, x
2 test), and 7 were currently
treated with azathioprine, 6-mercaptopurine, or methotrexate
(p=0.06, x
2 test). The cd-T cell levels were negatively correlated
with age (p=0.004, Spearman rho), with the highest cd-T cell
levels observed in young patients. In flow cytometric analysis we
found a strong Vd2 dominance within the cd-T cell population
(p=0.005, Spearman rho) (Figure 1A). Interestingly, we found no
statistically significant associations between the cd-T cell percent-
ages and the disease activity markers (i.e., the Harvey-Bradshaw
Index, faecal calprotectin, or C-reactive protein). This suggests
that CD-mediated inflammation was not responsible for the
observed changes in the cd-T cell populations (Figure 1B).
In Vivo Clonal Expansion of cd-T cells Induced by
Infliximab
Subsequently, we investigated the dynamic changes in cd-T cell
populations during anti-TNF-a therapy. To be able to identify the
direct effects and separate them from the secondary immunolog-
ical effects, we examined changes in cd-T cells at early points
during anti-TNF-a therapy. The majority of CD patients
exhibited only minor fluctuations in cd-T cell frequency.
However, in the subgroup of young male patients with high
baseline cd-T cells, we observed a dramatic increase following
treatment; in fact, the percentage of cd-T cells increased
significantly within the first 24 hours after a single infliximab
infusion (Figure 2).
In an attempt to confirm our findings that young male patients
with a high baseline percentage of cd-T cells appear to be prone to
further cd-T cell expansion during treatment with immunosup-
pressive drugs, we examined additional patients outside the
original CD cohort. We identified a 33-year-old male CD patient
(number 47) who had been treated with infliximab monotherapy
at 8-week intervals for 9 years. He presented with an extraordi-
narily high baseline frequency of cd-T cells (18–21% of all CD3+
T cells). These results were confirmed by three measurements
performed between infliximab treatments over a 6-month period
of stable clinical remission. From this high baseline frequency, the
cd-T cell population expanded to 25% 2 days after infliximab
infusion and to 36% 3 months after treatment. Clonotypically,
90% of the cd-T cells were Vd2, suggesting the existence of a
predominant cd-T cell clone. Genescan analysis, as well as
heteroduplex analysis, confirmed the monoclonal expansion of a
cd-T cell clone in the peripheral blood of this patient (Figure 3 A,
B).
While the expansion of cd-T cells was observed in CD patients
treated with infliximab, no significant changes were observed in
adalimumab-treated individuals. This finding was surprising, as
the majority of patients in this group had received adalimumab in
combination with additional immunosuppressive agents, such as
thiopurines or methotrexate. One male CD patient with cd-T cell
expansion during maintenance therapy with infliximab and
azathioprine was later shifted to adalimumab. Interestingly, unlike
patients on continued infliximab treatment, we detected no further
cd-T cell expansion in this ‘cross-over’ patient following the
change in therapy to adalimumab.
The Impact of Immunomodulators on cd-T cells
In adalimumab-treated CD patients, the baseline level of cd-T
cells (mean 3.9%) was slightly higher than the baseline level in
infliximab-treated CD patients (mean 2.7%) (p=0.27, Student’s t-
test). This finding may, in part, be explained by the slightly higher
frequency of patients treated with immunomodulators in the
adalimumab group. In CD patients that received azathioprine, 6-
mercaptopurine, or methotrexate, the baseline cd-T cell repre-
sented an average of 4.4% of all T cells, with values ranging from
2.1–6.7%; these results were not significantly different from those
found in CD patients not treated with immunomodulators
(p=0.17, Student’s t-test). However, these values were masked
by a subpopulation of CD patients with unusually high levels of
cd-T cells. Repeated blood sampling from this subgroup revealed
persistently high percentages of cd-T cells and we observed 8.5%
cd-T Cells in Crohn’s Disease
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Genescan analysis revealed a narrow oligoclonal cd-T cell pattern
with a dominant clone, which was confirmed by heteroduplex
analysis (Figure 3 C, D). These results suggest that immunomod-
ulators may induce proliferation and clonal selection of cd-T cells.
In Vitro Proliferation of cd-T cells Induced by Anti-TNF-a
Agents
In order to discriminate between the direct effects of anti-TNF-
a agents on cd-T cells and the secondary, indirect effects that are
mediated through the modulation of the inflammatory cytokine
milieu in vivo, we examined the impact of anti-TNF-a agents on
cd-T cells in vitro. An in vitro analysis of the effects of infliximab,
adalimumab, and the TNF-a receptor fusion protein etanercept
on cd-T cells would also allows us to exclude the possibility that
the observed increases in circulating cd-T cells was caused by a
redistribution of the intestinal pool of cd-T cells. When PBMCs
from CD patients and healthy controls were cultured for 5 days,
the anti-TNF-a agents induced the dose-dependent, selective
proliferation of cd-T cells in cultures supplemented with IL-2
(200 IU/ml). This proliferative effect was reversed by the addition
of recombinant TNF-a. Our findings with etanercept indicate that
neutralisation of TNF-a in the culture medium, rather than the
membrane-bound form of TNF-a, is involved (Figure 4). The
induced proliferation was of the same magnitude for all anti-TNF-
a agents. Proliferation was more pronounced in cd-T cells
compared to non-cd-T cells, resulting in a relative increase in
cd-T cell frequency compared to other lymphocyte populations.
Ustekinumab, an antibody against IL-12p40 that was used as a
negative control did not affect the cd-T cell frequency.
Importantly, we observed a proliferative effect of anti-TNF-a
agents on cd-T cells from both CD patients and healthy controls,
indicating that the proliferation of cd-T cells in response to anti-
TNF-a agents may not be restricted to CD patients.
Discussion
The clinical rationale for combined immunotherapy in the
management of CD is well established and has been strengthened
by the results of the recent SONIC study [22,23]. To date, the
consensus is that the clinical benefits of immunomodulators
outweigh the risk of lymphoma. Despite several case reports
Figure 1. Baseline cd-T cell characteristics in 46 CD patients. A) Of the 46 CD patients, 35 (76%) had a cd-T cell level comparable to healthy
volunteers, while 11 (24%) had a level ranging from 5 to 15% (left). The cd-T cell level correlated with the expression of the Vd2 subunit (middle), and
the cd-T cell levels correlated negatively with age (right). B) There were no statistically significant associations between cd-T cell levels and markers of
mucosal inflammation (faecal calprotectin), clinical disease activity (Harvey-Bradshaw Index), or systemic inflammation (C-reactive protein).
doi:10.1371/journal.pone.0017890.g001
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been possible to determine if the anti-TNF-a agents played a
primary role in the lymphomagenesis or if HSTCL should be
regarded as the result of a clonal evolution within the more
generalised chronic inflammatory processes that characterise IBD.
In the present study, we hypothesised that clonal cd-T cell
evolution, presumed to precede neoplastic transformation into
HSTCL, may be promoted by the repeated administration of anti-
TNF-a agents. In approximately 75% of CD patients, we observed
a cd-T cell frequency within the normal range (1–3% of all T cells).
However, in the remaining 25% of CD patients receiving
immunomodulatory therapy, we observed a persistently high
percentageofcd-Tcells;amongst these,young malepatientsappeared
to be more prone to a clonal cd-T cell expansion following repeated
infliximab infusion. In addition, the analysis of TCRD rearrangements
revealed a dominant clone in a female patient receiving monotherapy
with 6-mercaptopurine, supporting the idea of stepwise clonal
selection of cd-T cells during combined immunotherapy.
These findings are difficult to interpret as being completely
drug-induced as CD patients may have an increased number of
Figure 2. The cd-T cell level of three CD patients who were treated with infliximab increased shortly after infliximab infusion. A) The
results from two representative young male CD patients are shown. B) Illustration of the gating strategy. Using multicolour flow cytometry, cd-T cells
were identified by positive gating on live lymphocytes based on forward/side scatter (left panel), the selection of both CD4+ and CD4- cells among
the CD3+ T cells (middle panel), and the separation of cd-T cells from ab-T cells (right panel).
doi:10.1371/journal.pone.0017890.g002
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associated with this disease [2,3,24]. One explanation could be
cd-T cell recruitment from the inflamed intestinal mucosa, where
cd-T cells are abundant. However, new evidence challenges this
hypothesis due to the lack of identical cd-T cell clones in the
intestinal mucosa and peripheral blood of CD patients [24].
Furthermore, a direct neoplastic effect on cd-T cells cannot be
ruled out. In fact, whether the chronic inflammation itself is
Figure 3. Analysis of TCRD rearrangement and heteroduplex analysis confirms the clonal expansion of cd-T cells. For the fragment and
heteroduplex analyses two representative examples of three CD patients are shown. A) Genescan analysis of patient number 47 shows a single
monoclonal peak at 199 bp with a fluorescence intensity of 3574. B) Heteroduplex analysis of the same sample demonstrates a dominant band of
approximately 200 bp. C) Genescan of patient number 8 shows a single monoclonal peak at 184 bp with a fluorescence intensity of 7120. D)
Heteroduplex analysis of the same sample shows a very prominent band in the range of 180–190 bp. E) Genescan of a healthy control shows various
polyclonal bands with different sizes and generally low fluorescence intensity. F) Heteroduplex analysis of the same sample resulted in a DNA smear
with weak fluorescence intensity.
doi:10.1371/journal.pone.0017890.g003
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in CD patients is still a matter of contention within the field [12].
Hence, the increased number of cd-T cells in CD patients may
simply reflect the degree of intestinal inflammation, and patients
with refractory or uncontrolled inflammation may therefore be
overrepresented in the group receiving thiopurines. However, in
our study we did not find a significant correlation between the
percentage of cd-T cells and key inflammatory markers.
Furthermore, inflammation certainly cannot explain the massive
increase in cd-T cells seen after infliximab treatment in cases
where the disease activity index and systemic and intestinal
inflammatory markers declined.
This study was focused on investigating the impact of immuno
suppressive therapy on cd-T cells and its possible role in
lymphomagenesis thus allowing the identification of at risk patients.
Our results indicate that cd-T cells can be modulated by anti-TNF-
a therapy in vitro, which may represent a first step to substantiate a
causal role of infliximab in cd-T cell malignancies. In this context,
we measured changes in the frequency of cd-T cells in the
peripheralbloodof CDpatients asearly as 24 hoursafter infliximab
infusion. Three male patients showed a marked response, nearly
doubling their number of cd-T cells. The observed changes in cd-T
cells appeared robust compared with the minor changes we
observed in other lymphocyte subpopulations [25].In the light of
the well-known preponderance of cases of HSTCL in males, it is
noteworthy that our study only demonstrated high levels of cd-T
cell expansion in male CD patients. As a proof of concept, we
analysed the peripheral blood of a CD patient who had undergone
long-term treatment with infliximab (9 years). Interestingly, we
found unusually high levels of cd-T cells (on average 20% of all T
cells), which increased further to 36% during the study period.
Genescan analysis of TCRD rearrangements in cells from this
patient showed a clonal expansion of cd-T cells, which was
confirmed by heteroduplex analysis. This finding, together with our
in vitro data, suggests the infliximab-induced clonal expansion of
cd-T cells in the peripheral blood rather than a redistribution of the
intestinal cd-T cells. Furthermore, the expanded cd-T cells were
mainly of the Vd2 subtype, and not d-1, as one would expect if they
were of mucosal origin [1]. However, we cannot yet say that this
dominant clone actually represents a premalignant transformation
as oligoclonal cd-T cell populations are occasionally found in CD
patients without the development of lymphomas [24]. Additionally,
we do not have data confirming that the same cd-T cell clone
actually expanded as a direct consequence of repeated infliximab
infusions. However, it is remarkable that the strongest increase in
the proportion of cd-T cells was seen in young males receiving
infliximab.
The mechanisms underlying the action of thiopurines in the
treatment of IBD are poorly understood [26]. The observed
increased frequency of cd-T cells following treatment with
thiopurines may be a double-edged sword, as cd-T cell expansion
could represent a principal therapeutic mechanism in CD, while at
the same time predisposing the patient to lymphoma. Gene
expression profiling has recently established that cd-T cell
lymphomas have distinct molecular signatures [4]. In the future,
various gene profiling strategies may be able to identify
premalignant genetic lesions in CD patients receiving combined
immunotherapy [27,28].
The proliferation of cd-T cells in vivo was not seen in patients
treated with adalimumab. We believe that this could be the result
of the chosen observation window, dosage, or method of
administration (subcutaneous vs. intravenous) rather than a
genuine difference in intrinsic therapeutic mechanisms. Our in
vitro data suggest that the cd-T cell expansion is a dose-dependent
effect of multiple anti-TNF-a reagents. However, a valid in vivo
comparison of the drugs is difficult to undertake, as the
conventional clinical algorithm dictates that most CD patients
on adalimumab will have received infliximab earlier. It should be
noted, however that lower doses of infliximab are recommended (3
vs. 5 mg/kg) in the treatment of rheumatoid arthritis, which might
explain the single case of HSTCL that has been reported in
patients with rheumatoid arthritis.
We present an example of how epidemiological data can be
translated to the patient level and further to the in vitro level. Our
results confirm earlier findings that the number of cd-T cells is
increased in a subgroup of CD patients; however, in our study, the
increased cd-T cell frequency was independent of disease activity.
A subset of CD patients treated with thiopurines or methotrexate
had an extremely high baseline frequency of cd-T cells. These
patients appear to have a lower threshold for expansion of cd-T
cells when treated with infliximab, which we found to be a potent
inducer of cd-T cells in vitro. Further studies are warranted to
substantiate our observation that inflixmab may promote lympho-
magenesis by the repeated clonal expansion of cd-T cells.
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